Titan Pharma announces JAMA publication highlighting phase 3 opioid dependence data

Probuphine's innovative implant formulation demonstrates compelling efficacy in patients suffering from opioid addiction

2010-10-13

(Press-News.org) South San Francisco, CA – October 12, 2010 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA). The article highlights data from the 163-patient trial, which showed that patients receiving Titan's Probuphine implant had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement when compared to placebo patients over the course of the 24-week study.

Probuphine is an innovative, subcutaneous implant formulation designed using Titan's proprietary ProNeura™ technology to deliver a steady, round-the-clock low dose of the marketed drug buprenorphine over six months following a single treatment.

"The introduction of buprenorphine into clinical practice is arguably the most significant improvement in the treatment of opioid addiction in the last decade; however, physicians excited with the clinical success of buprenorphine are also rightfully concerned about medication adherence and diversion - and potential for abuse - of the sublingual formulations of buprenorphine," said Walter Ling, M.D., Professor of Psychiatry and Director, Integrated Substance Abuse Programs at the David Geffen School of Medicine at UCLA and the paper's lead author. "Probuphine does away with these concerns by eliminating the need for take home doses. Additionally, by providing a sustained blood level of active medication, Probuphine helps diminish the daily fluctuation of the medication effects—and potentially side effects-- and reduces the total exposure of buprenorphine over time."

The publication, "Buprenorphine Implants for Opioid Dependence: A Randomized Controlled Trial" will appear in the October 13, 2010 issue of JAMA and details key trial results: Patients receiving Probuphine had a mean percentage of urine samples that tested negative for illicit opioids across the full 24 weeks of 36.6 percent; those in the placebo group had a mean of 22.4 percent (p=0.01) Nearly 66 percent of patients receiving Probuphine completed the study vs. the 31 percent who received placebo implants (p END

ELSE PRESS RELEASES FROM THIS DATE:

Despite brain damage, working memory functions -- within limits

2010-10-13

Researchers at the University of California, San Diego School of Medicine, led by Larry R. Squire, PhD, professor of psychiatry, psychology and neurosciences at UC San Diego and a scientist at the VA San Diego Healthcare System, report that working memory of relational information – where an object is located, for example – remains intact even if key brain structures like the hippocampus are damaged. The findings, published in the October 13, 2010 issue of The Journal of Neuroscience, run contrary to previous research that suggested spatial information, especially if ...

Diagnosing autism with MRI is 1 step closer

2010-10-13

SALT LAKE CITY—University of Utah (U of U) medical researchers have made an important step in diagnosing autism through using MRI, an advance that eventually could help health care providers indentify the problem much earlier in children and lead to improved treatment and outcomes for those with the disorder. In a study published on October 15, 2010 in Cerebral Cortex online, researchers led by neuroradiologist Jeffery S. Anderson, M.D., Ph.D., U of U assistant professor of radiology, used MRI to identify areas where the left and right hemispheres of the brains of people ...

Forget the Coppertone: Water fleas in mountain ponds can handle UV rays

2010-10-13

Some tiny crustaceans living in clear-water alpine ponds high in Washington state's Olympic Mountains have learned how to cope with the sun's damaging ultraviolet rays without sunblock – and with very little natural pigmentation to protect them. In fact, in laboratory tests these water fleas, about the size of fruit flies, withstood UV rays much better than the same species of flea taken from a pond less than a mile away, where the water was murkier and thus offered protection. "The ponds pretty much look the same to us, but the environments are very different for ...

Fox Chase researchers uncover Achilles' heel in aggressive breast tumors

2010-10-13

PHILADELPHIA (October 12, 2010)—In an unexpected twist, Fox Chase Cancer Center researchers find that the loss of a single protein, Nedd9, initially slows cancer formation but then makes the tumors that do arise more aggressive. The good news, though, is that the lack of Nedd9 also makes the aggressive tumors more sensitive to a class of drugs that are already used in the clinic. "If a tumor is able to overcome the loss of this protein, this clearly makes it undergo complicated changes that ultimately select for a more aggressive tumor," says Erica A. Golemis, Ph.D., ...

Promising drug candidate reverses age-related memory loss in mice

2010-10-13

Researchers at the University of Edinburgh today report a new experimental compound that can improve memory and cognitive function in ageing mice. The compound is being investigated with a view to developing a drug that could slow the natural decline in memory associated with ageing. With support from a Wellcome Trust Seeding Drug Discovery award, the team has identified a preclinical candidate that they hope to take into human trials within a year. Many people find they become more forgetful as they get older and we generally accept it as a natural part of the ageing ...

Patients and doctors are being misled by published data on medicines

2010-10-13

The drug reboxetine is, overall, an ineffective and potentially harmful antidepressant, according to a comprehensive study of the evidence published on bmj.com today. The study also shows that nearly three quarters of the data on patients who took part in trials of reboxetine were not published until now, and that the published data on the drug overestimate the benefits and underestimate the harms of treatment - all underlining the urgent need for mandatory publication of all clinical trial results. Reboxetine has been approved for the treatment of major depressive ...

Are patient surveys a reliable way to assess the performance of doctors and practices?

2010-10-13

To assess the performance of general practices, it is better to ask patients about their actual experiences of care rather than ask for satisfaction ratings, according to new research published on bmj.com today. The findings call into question the reliability of using surveys to evaluate practice performance. Patient surveys are used to assess the performance of doctors and practices, and they increasingly enquire about specific patient experiences (e.g. waiting time for an appointment) as well as overall satisfaction. In the UK, general practices receive some of ...

Long-lasting mechanical heart implanted for the first time in Canada in heart-failure patient

2010-10-13

In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD – a major drawback with the old technology. The patient, 61-year-old Marva Lorde of Mississauga, suffered a heart attack in 2007 and underwent several treatments for heart failure – including a 10-day intensive care unit stay, angioplasty and pacemaker implantation –culminating in a cardiac arrest in June 2008. "I ...

Georgia Tech mobile phone game trains players to make healthier diet selections

2010-10-13

With Halloween and the holiday season fast approaching, many people will be watching their waistlines as they're tempted by a cornucopia of sugary and savory foods. Meanwhile a Georgia Tech College of Computing Ph.D. candidate has shown that playing health-related video games on a mobile device can help adults learn to live more healthfully by making smart diet choices. The finding is published in the paper, "Let's Play! Mobile Health Games for Adults," recently presented at Ubicomp 2010 in Copenhagen, Denmark. OrderUP! is a different take on the recent trend of health-related ...

Rotten experiments help to create picture of our early ancestors

2010-10-13

An innovative experiment at the University of Leicester that involved studying rotting fish has helped to create a clearer picture of what our early ancestors would have looked like. The scientists wanted to examine the decaying process in order to understand the decomposition of soft-body parts in fish. This in turn will help them reconstruct an image of creatures that existed 500 million years ago. Their findings have been published today, Wednesday 13th October, in the journal Proceedings of the Royal Society B. The work was funded by the Natural Environment Research ...

Titan Pharma announces JAMA publication highlighting phase 3 opioid dependence data

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: